Camptothecin and Analogs

Natural Products in Medicinal Chemistry

Volumn , Issue , 2014, Pages 181-224

  Giannini, Giuseppe ^a  

^a Sigma Tau SpA   (Italy)

Author keywords

Camptothecin; CPT in clinical trials; Current perspective on CPT; Ethnomedicine; HomoCPT; Modern chromatographic method applied to CPT; Selective tumor targeting; Synthesis of CPT; Topoisomerase I inhibitors; Topoisomerases

Indexed keywords

EID: 84926442927     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527676545.ch05     Document Type: Chapter

References (136)

1. Wall, M.E., Wani, M.C., Cook, C.E., Palmer, K.H., McPhail, A.T., and Sim, G.A. (1966) Plant antitumor agents: 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. Journal of the American Chemical Society, 88, 3888-3890.
2. Glaberman, U., Rabinowitz, I., and Verschraegen, C.F. (2005) Alternative administration of camptothecin analogues. Expert Opinion on Drug Delivery, 2, 323-333.
3. Hsiang, Y.H., Hertzberg, R., Hecht, S., and Liu, L.F. (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. The Journal of Biological Chemistry, 260, 14873-14878.
4. Kingsbury, W.D., Boehm, J.C., Jakas, D.R., Holden, K.G., Hecht, S.M., Gallagher, G., Caranfa, M.J., McCabe, F.L., Faucette, L.F., and Johnson, R.K. (1991) Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. Journal of Medicinal Chemistry, 34, 98-107.
5. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Research, 51, 4187-4191.
6. Garcia-Carbonero, R. and Supko, J.G. (2002) Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clinical Cancer Research, 8, 641-661.
7. Atsumi, R., Okazaki, O., and Hakusui, H. (1995) Metabolism of irinotecan to SN-38 in a tissue-isolated tumor model. Biological & Pharmaceutical Bulletin, 18, 1024.
8. Venditto, V.J. and Simanek, E.E. (2010) Cancer therapies utilizing the camptothecins: a review on the in vivo literature. Molecular Pharmaceutics, 7 (2), 307-349.
9. Kroep, J.R. and Gelderblom, H. (2009) Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opinion on Investigational Drugs, 18 (1), 69-75.
10. Hautefaye, P., Cimetiere, B., Pierre, A., Leonce, S., Hickman, J., Laine, W., Bailly, C., and Lavielle, G. (2003) Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin. Bioorganic & Medicinal Chemistry Letters, 13, 2731-2735.
11. Lansiaux, A., Leonce, S., Kraus-Berthier, L., Bal-Mahieu, C., Mazinghien, R., Didier, S., David-Cordonnier, M.-H., Hautefaye, P., Lavielle, G., Bailly, C., Hickman, J.A., and Pierre, A. (2007) Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs. Molecular Pharmacology, 72, 311-319.
12. Champoux, J.J. (2012) DNA topoisomerases and cancer, in Human DNA Topoisomerase I: Structure, Enzymology and Biology (ed. Y. Pommier), Springer, New York, pp. 53-69.
13. Wang, J.C. (1971) Interaction between DNA and an Escherichia coli protein v. Journal of Molecular Biology, 55, 523-533.
14. Liu, L.F., Liu, C.-C., and Alberts, B.M. (1980) Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell, 19, 697-707.
15. Pommier, Y., Leo, E., Zhang, H., and Marchand, C. (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chemistry & Biology, 17, 421-433.
16. Gast, A. (2010) Unraveling the catalytic mechanism of topoisomerase V, Senior Honors Thesis, Northwestern University, Chicago, IL, pp. 1-65.
17. Baker, N.M., Rajan, R., and Mondragón, A. (2009) Structural studies of type I topoisomerases. Nucleic Acids Research, 37, 693-701.
18. Corbett, K.D. and Berger, J.M. (2004) Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annual Review of Biophysics and Biomolecular Structure, 33, 95-118.
19. Pommier, Y. and Marchand, C. (2012) Interfacial inhibitors: targeting macromolecular complexes. Nature Reviews. Drug Discovery, 11, 25-36.
20. Staker, B.L., Hjerrild, K., Feese, M.D., Behnke, C.A., Burgin, A.B., and Stewart, L. (2002) The mechanism of topoisomerase I poisoning by a camptothecin analog. Proceedings of the National Academy of Sciences of the United States of America, 99, 15387-15392.
21. Staker, B.L., Feese, M.D., Cushman, M., Pommier, Y., Zembower, D., Stewart, L., and Burgin, A.B. (2005) Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. Journal of Medicinal Chemistry, 48 (7), 2336-2345.
22. Marchand, C., Antony, S., Kohn, K.W., Cushman, M., Ioanoviciu, A., Staker, B.L., Burgin, A.B., Stewart, L., and Pommier, Y. (2006) A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of topoisomerase I-DNA covalent complexes. Molecular Cancer Therapeutics, 5 (2), 287-295.
23. Wang, X., Wang, L.-K., Kingsbury, W.D., Johnson, R.K., and Hecht, S.M. (1998) Differential effects of camptothecin derivatives on topoisomerase I-mediated DNA structure modification. Biochemistry, 37 (26), 9399-9408.
24. Redinbo, M.R., Stewart, L., Kuhn, P., Champoux, J.J., and Hol, W.G. (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science, 279, 1504-1513.
25. Padlan, E.A. and Kabat, E.A. (1991) Modeling of antibody combining sites. Methods in Enzymology, 203, 3-21.
26. Laco, G.S., Collins, J.R., Luke, B.T., Kroth, H., Sayer, J.M., Jerina, D.M., and Pommier, Y. (2002) Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model. Biochemistry, 41 (5), 1428-1435.
27. Kerrigan, J.E. and Pilch, D.S. (2001) A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin. Biochemistry, 40 (33), 9792-9798.
28. Siu, Fung-Ming and Che, Chi-Ming (2008) Persistence of camptothecin analog-topoisomerase I-DNA ternary complexes: a molecular dynamics study. Journal of the American Chemical Society, 130, 17928-17937.
29. Chrencik, J.E., Staker, B.L., Burgin, A.B., Pourquier, P., Pommier, Y., Stewart, L., and Redinbo, M.R. (2004) Mechanisms of camptothecin resistance by human topoisomerase I mutations. Journal of Molecular Biology, 339 (4), 773-784.
30. Jaxel, C., Kohn, K.W., Wani, M.C., Wall, M.E., and Pommier, Y. (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Research, 49, 1465-1469.
31. Miao, Z.H., Player, A., Shankavaram, U., Wang, Y.H., Zimonjic, D.B., Lorenzi, P.L., Liao, Z.Y., Liu, H., Shimura, T., Zhang, H.L., Meng, L.H., Zhang, Y.W., Kawasaki, E.S., Popescu, N.C., Aladjem, M.I., Goldstein, D.J., Weinstein, J.N., and Pommier, Y. (2007) Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Research, 67 (18), 8752-8761.
32. Husain, I., Mohler, J.L., Seigler, H.F., and Besterman, J.M. (1994) Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Research, 54 (2), 539-546.
33. Potmesil, M. (1994) Camptothecins: from bench research to hospital wards. Cancer Research, 54 (6), 1431-1439.
34. Giannini, G., Cabri, W., Fattorusso, C., and Rodriquez, M. (2012) Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Medicinal Chemistry, 4 (11), 1439-1460.
35. Ayrton, A. and Morgan, P. (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica; The Fate of Foreign Compounds in Biological Systems, 31, 469-497.
36. Rasheed, Z.A. and Rubin, E.H. (2003) Mechanisms of resistance to topoisomerase I targeting drugs. Oncogene, 22, 7296-7304.
37. Nitiss, J. and Wang, J.C. (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proceedings of the National Academy of Sciences of the United States of America, 85, 7501-7505.
38. Pommier, Y. (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nature Reviews. Cancer, 6 (10), 789-802.
39. Baranello, L., Bertozzi, D., Fogli, M.V., Pommier, Y., and Capranico, G. (2010) DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1a gene locus. Nucleic Acids Research, 38 (1), 159-171.
40. Huang, H.S., Allen, J.A., Mabb, A.M., King, I.F., Miriyala, J., Taylor-Blake, B., Sciaky, N., Dutton, J.W., Lee, H.-M., Chen, X., Jin, J., Bridges, A.S., Zylka, M.J., Roth, B.L., and Philpot, B.D. (2012) Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature, 481, 185-189.
41. Basili, S. and Moro, S. (2009) Novel camptothecin derivatives as topoisomerase I inhibitors. Expert Opinion on Therapeutic Patents, 19, 555-574.
42. Feun, L. and Savaraj, N. (2008) Topoisomerase I inhibitors for the treatment of brain tumors. Expert Review of Anticancer Therapy, 8 (5), 707-716.
43. Moukharskaya, J. and Claire Verschraegen, C. (2012) Topoisomerase 1 inhibitors and cancer therapy. Hematology/Oncology Clinics of North America, 26, 507-525.
44. Schluep, T., Cheng, J., Khin, K.T. et al. (2006) Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemotherapy and Pharmacology, 7, 654-662.
45. Schluep, T., Hwang, J., Cheng, J. et al. (2006) Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clinical Cancer Research, 12, 1606-1614.
46. Sausville, E.A., Garbo, L.E., Weiss, G.J., Shkolny, D., Yurkovetskiy, A.V., Bethune, C., Ramanathan, R., and Fram, R.J. (2009) A phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an intravenous infusion once every three weeks to patients with advanced solid tumors.. Molecular Cancer Therapeutics, 8 (12), B52. www.mersana.com/objects/docs/AACR_Poster_2009_11-02-09.pdf.
47. Liu, X., DeJesus, A., Cao, Z., Vardeman, D., and Giovanella, B. (2012) Metabolic difference of CZ48 in human and mouse liver microsomes. International Journal of Molecular Sciences, 13, 5498-5505.
48. Underberg, W.J., Goossen, R.M., Smith, B. R., and Beijnen, J.H. (1990) Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. Journal of Pharmaceutical and Biomedical Analysis, 8, 681-683.
49. Neuhaus, T., Ko, Y., Muller, R.P., Grabenbauer, G.G., Hedde, J.P., Schueller, H., Kocher, M., Stier, S., and Fietkau, R. (2009) A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. British Journal of Cancer, 100, 291-297.
50. Herzog, T.J. (2002) Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist, 7 (Suppl. 5), 3-10.
51. Riemsma, R., Simons, J.P., Bashir, Z., Gooch, C.L., and Kleijnen, J. (2010) Systematic review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC Cancer, 10, 436.
52. Huang, G., Wang, H., and Yang, L.X. (2010) Enhancement of radiation induced DNA damage and inhibition of its repair by a novel camptothecin analog. Anticancer Research, 30, 937-944.
53. Sawada, S., Okajima, S., Aiyama, R., Nokata, K.-I., Furata, T., Yokpkura, T., Sugimo, E., Yamaguchi, K., and Miyasaka, T. (1991) Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chemical & Pharmaceutical Bulletin, 39 (6), 1446-1450.
54. Mathijssen, R.H., van Alphen, R.J., Verweij, J., Loos, W.J., Nooter, K., Stoter, G., and Sparreboom, A. (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clinical Cancer Research, 7 (8), 2182-2194.
55. Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Niitani, H., and Taguchi, T. (1991) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. Journal of the National Cancer Institute, 83 (16), 1164-1168.
56. Sapra, P., Zhao, H., Mehlig, M., Malaby, J., Kraft, P., Longley, C., Greenberger, L.M., Ivan, D., and Horak, I.D. (2008) Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11 -refractory model. Clinical Cancer Research, 14, 1888-1896.
57. Banerjee, S.S., Aher, N., Patil, R., and Jayant Khandare, J. (2012) Poly(ethylene glycol)-prodrug conjugates: concept, design, and applications. Journal of Drug Delivery, 2012, 1-17.
58. Zhao, H., Rubio, B., Sapra, P., Wu, D., Reddy, P., Sai, P., Martinez, A., Gao, Y., Lozanguiez, Y., Longley, C., Greenberger, L.M., and Horak, I.D. (2008) Novel prodrugs of SN38 using multiarm poly (ethylene glycol) linkers. Bioconjugate Chemistry, 19 (4), 849-859.
59. Verschraegen, C.F., Gupta, E., Loyer, E., Kavanagh, J.J., Kudelka, A.P., Freedman, R.S., Edwards, C.L., Harris, N., Steger, M., Steltz, V., Giovanella, B.C., and Stehlin, J.S. (1999) A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anti-Cancer Drugs, 10 (4), 375-383.
60. Tedesco, K.L., Berlin, J., Rothenberg, M., Choy, H., Wyman, K., Scott Pearson, A., Daniel Beauchamp, R., Merchant, N., Lockhart, A.C., Shyr, Y., Caillouette, C., and Chakravarthy, B. (2005) A phase I study of concurrent 9-nitro-20(S)-camptothecin (9 NC/orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. Radiotherapy & Oncology, 76 (1), 54-58.
61. Duan, J.-X., Cai, X., Meng, F., Sun, J.D., Liu, Q., Jung, D., Jiao, H., Matteucci, J., Jung, B., Bhupathi, D., Ahluwalia, D., Huang, H., Hart, C.P., and Matteucci, M. (2011) 14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment. Journal of Medicinal Chemistry, 54, 1715-1723.
62. Ulukan, H. and Swaan, P.W. (2002) Camptothecins: a review of their chemotherapeutic potential. Drugs, 62, 2039-2057.
63. Duffaud, F., Borner, M., Chollet, P., Vermorken, J.B., Bloch, J., Degardin, M., Rolland, F., Dittrich, C., Baron, B., Lacombe, D., and Fumoleau, P. (2004) Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. European Journal of Cancer (Oxford, England: 1990), 40 (18), 2748-2752.
64. Emerson, D.L., Bendele, R., Brown, E., Chiang, S., Desjardins, J.P., Dihel, L.C., Gill, S.C., Hamilton, M., LeRay, J.D., Moon-McDermott, L., Moynihan, K., Richardson, F.C., Tomkinson, B., Luzzio, M.J., and Baccanari, D. (2000) Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Clinical Cancer Research, 6 (7), 2903-2912.
65. Royce, M.E., Hoff, P.M., Dumas, P., Lassere, Y., Lee, J.J., Coyle, J., Ducharme, M.P., De Jager, R., and Pazdur, R. (2001) Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. Journal of Clinical Oncology, 19 (5), 1493-1500.
66. Abou-Alfa, G.K., Letourneau, R., Harker, G., Modiano, M., Hurwitz, H., Tchekmedyian, N.S., Feit, K., Ackerman, J., De Jager, R.L., Eckhardt, S.G., and O'Reilly, E.M. (2006) Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. Journal of Clinical Oncology, 24 (27), 4441-4447.
67. Esteva, F.J., Rivera, E., Cristofanilli, M., Valero, V., Royce, M., Duggal, A., Colucci, P., DeJager, R., and Hortobagyi, G.N. (2003) A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer, 98 (5), 900-907.
68. Verschraegen, C.F., Kudelka, A.P., Hu, W., Vincent, M., Kavanagh, J.J., Loyer, E., Bastien, L., Duggal, A., and De Jager, R. (2004) A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer Chemotherapy and Pharmacology, 53 (1), 1-7.
69. Cheverton, P.F.H., Andras, C., Salek, T., Geddes, C., Bodoky, G., Valle, J., and Humblet, Y. (2004) Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC). Journal of Clinical Oncology, 22, 4005.
70. Abou-Alfa, G.K., Letourneau, R., Harker, G., Modiano, M., Hurwitz, H., Tchekmedyian, N.S., Feit, K., Ackerman, J., De Jager, R.L., Eckhardt, S.G., and O'Reilly, E.M. (2006) Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. Journal of Clinical Oncology, 24 (27), 4441-4447.
71. Frapolli, R., Zucchetti, M., Sessa, C., Marsoni, S., Viganó, L., Locatelli, A., Rulli, E., Compagnoni, A., Bello, E., Pisano, C., Carminati, P., and D'Incalci, M. (2010) Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels. European Journal of Cancer (Oxford, England: 1990), 46 (3), 505-516.
72. Di Francesco, A.M., Riccardi, A., Barone, G., Rutella, S., Meco, D., Frapolli, R., Zucchetti, M., D'Incalci, M., Pisano, C., Carminati, P., and Riccardi, R. (2005) The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan. Biochemical Pharmacology, 70 (8), 1125-1136.
73. Pecorelli, S., Ray-Coquard, I., Tredan, O., Colombo, N., Parma, G., Tisi, G., Katsarós, D., Lhommé, C., Lissoni, A.A., Vermorken, J.B., du Bois, A., Poveda, A., Frigerio, L., Barbieri, P., Carminati, P., Brienza, S., and Guastalla, J.P. (2010) Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Annals of Oncology, 21 (4), 759-765.
74. Choi, C.H., Lee, Y.Y., Song, T.J., Park, H.S., Kim, M.K., Kim, T.J., Lee, J.W., Lee, J.H., Bae, D.S., and Kim, B.G. (2011) Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer. Cancer, 117 (10), 2104-2111.
75. Hong, J., Jung, M., Kim, Y.J., Sym, S.J., Kyung, S.Y., Park, J., Lee, S.P., Park, J.W., Cho, E.K., Jeong, S.H., Shin, D.B., and Lee, J.H. (2012) Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. Cancer Chemotherapy and Pharmacology, 69 (1), 215-220.
76. Horn, J., Milewska, M., Arnold, S.M., and Leggas, M. (2011) Metabolic pathways of the camptothecin analog AR-67. Drug Metabolism and Disposition, 39 (4), 683-692.
77. Yeh, T.K., Li, C.M., Chen, C.P., Chuu, J.J., Huang, C.L., Wang, H.S., Shen, C.C., Lee, T.Y., Chang, C.Y., Chang, C.M., Chao, Y.S., Lin, C.T., Chang, J.Y., and Chen, C.T. (2010) Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91. Pharmacological Research, 61 (2), 108-115.
78. Gabarda, A.E., Du, W., Isarno, T., Tangirala, R.S., and Curran, D.P. (2002) Asymmetric total synthesis of (20R)-homocamptothecin, substituted homocamptothecins and homosilatecans. Tetrahedron, 58, 6329-6341.
79. Chatterjee, A., Digumarti, R., Mamidi, R.N., Katneni, K., Upreti, V.V., Uppalapati, S., Jiwatani, S., Srinivas, N.R., and Subramaniam, S. (2002) DRF-1042, a novel orally active camptothecin (CPT) analog: safety, pharmacokinetic (PK) and pharmacodynamic evaluation in a phase I dose escalation study. Proceedings of the American Society of Clinical Oncology, 21, Abstract 384.
80. Chatterjee, A., Digumarti, R., Katneni, K., Upreti, V.V., Mamidi, R.N.V.S., Mullangi, R., Surath, A., Srinivas, M.L., Uppalapati, S., Jiwatani, S., and Srinivas, N.R. (2005) Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study. Journal of Clinical Pharmacology, 45, 453-460.
81. Beretta, G.L., Zuco, V., De Cesare, M., Perego, P., and Zaffaroni, N. (2012) Namitecan: a hydrophilic camptothecin with a promising preclinical profile. Current Medicinal Chemistry, 19 (21), 3488-3501.
82. Pisano, C., De Cesare, M., Beretta, G.L., Zuco, V., Pratesi, G., Penco, S., Vesci, L., Foderá, R., Ferrara, F.F., Guglielmi, M.B., Carminati, P., Dallavalle, S., Morini, G., Merlini, L., Orlandi, A., and Zunino, F. (2008) Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968. Molecular Cancer Therapeutics, 7 (7), 2051-2059.
83. Cassinelli, G., Zuco, V., Petrangolini, G., De Cesare, M., Tortoreto, M., Lanzi, C., Cominetti, D., Zaffaroni, N., Orlandi, A., Passeri, D., Meco, D., Di Francesco, A. M., Riccardi, R., Bucci, F., Pisano, C., and Zunino, F. (2012) The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects. Biochemical Pharmacology, 84 (2), 163-171.
84. Tangirala, R.S., Antony, S., Agama, K., Pommier, Y., Anderson, B.D., Bevins, R., and Curran, D.P. (2006) Synthesis and biological assays of E-ring analogs of camptothecin and homocamptothecin. Bioorganic & Medicinal Chemistry, 14 (18), 6202-6212.
85. Patrick Philippart, P., Luke Harper, L., Chaboteaux, C., Decaestecker, C., Bronckart, Y., Gordover, L., Lesueur-Ginot, L., Malonne, H., Lavergne, O., Bigg, D.C.H., da Costa, P.M., and Kiss, R. (2000) Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions. Clinical Cancer Research, 6, 1557.
86. Soto, E., Keizer, R.J., Trocóniz, I.F., Huitema, A.D., Beijnen, J.H., Schellens, J. H., Wanders, J., Cendrós, J.M., Obach, R., Peraire, C., Friberg, L.E., and Karlsson, M.O. (2011) Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. Investigational New Drugs, 29 (5), 984-995.
87. Graham, J.S., Falk, S., Samuel, L.M., Cendros, J.M., and Evans, T.R. (2009) A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy. Cancer Chemotherapy and Pharmacology, 63 (5), 945-952.
88. Demarquay, D., Huchet, M., Coulomb, H., Lesueur-Ginot, L., Lavergne, O., Camara, J., Kasprzyk, P.G., Prévost, G., and Bigg, D.C. (2004) BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo. Cancer Research, 64 (14), 4942-4949.
89. Trocóniz, I.F., Cendrós, J.M., Soto, E., Pruñonosa, J., Perez-Mayoral, A., Peraire, C., Principe, P., Delavault, P., Cvitkovic, F., Lesimple, T., and Obach, R. (2012) Population pharmacokinetic/ pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a phase I dose finding study in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 70 (2), 239-250.
90. Huang, Q., Wang, L., and Lu, W. (2013) Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents. European Journal of Medicinal Chemistry, 63 (2013) 746-757.
91. Luo, Y., Yu, S., Tong, L., Huang, Q., Lu, W., and Chen, Y. (2012) Synthesis and biological evaluation of new homocamptothecin analogs. European Journal of Medicinal Chemistry, 54, 281-286.
92. Stork, G. and Schultz, A.G.J. (1971) Total synthesis of D,L-camptothecin. Journal of the American Chemical Society, 93 (16), 4074-4075.
93. Danishefsky, S.J., Etheredge, S.J., Volkmann, R., Eggler, J., and Quick, J. (1971) Nucleophilic additions to allenes: new synthesis of alpha-pyridones. Journal of the American Chemical Society, 93, 5575-5576.
94. Corey, E.J., Crouse, D.N., and Anderson, J.E. (1975) Total synthesis of natural 20(S)-camptothecin. The Journal of Organic Chemistry, 40 (14), 2140-2141.
95. Ejima, A., Terasawa, H., Sugimori, M., and Tagawa, H. (1989) Asymmetric synthesis of (S)-camptothecin. Tetrahedron Letters, 30, 2639-2640.
96. Li, Q.Y., Zu, Y.G., Shi, R.Z., and Yao, L.P. (2006) Review camptothecin: current perspectives. Current Medicinal Chemistry, 13 (17), 2021-2039.
97. Du, W. (2003) Towards new anticancer drugs: a decade of advances in synthesis of camptothecins and related alkaloids. Tetrahedron, 59, 8649-8687.
98. Comins, D.L. and Nolan, J.M. (2001) A practical six-step synthesis of (S)-camptothecin. Organic Letters, 3 (26), 4255-4257.
99. Curran, D.P. and Liu, H. (1992) New 4{thorn}1 radical annulations: a formal total synthesis of ({thorn})-camptothecin. Journal of the American Chemical Society, 114, 5863-5864.
100. Yabu, K., Masumoto, S., Yamasaki, S., Hamashima, Y., Kanai, M., Du, W., Curran, D.P., and Shibasaki, M. (2001) Switching enantiofacial selectivities using one chiral source: catalytic enantioselective synthesis of the key intermediate for (20S)-camptothecin family by (S)-selective cyanosilylation of ketones. Journal of the American Chemical Society, 123 (40), 9908-9909.
101. Yabu, K., Masumoto, S., Kanai, M., Curran, D.P., and Shibasaki, M. (2002) Studies toward practical synthesis of (20S)-camptothecin family through catalytic enantioselective cyanosilylation of ketones: improved catalyst efficiency by ligand-tuning. Tetrahedron Letters, 43, 2923.
102. Fortunak, J.M.C., Mastrocola, A.R., Mellinger, M., Sisti., N.J., Wood, J.L., and Zhuang, Z.-P. (1996) Novel syntheses of camptothecin alkaloids, Part I. Intramolecular [4{thorn}2] cycloadditions of N-arylimidates and 4H-3,1-benzoxazin-4-ones as 2-aza-1,3-dienes. Tetrahedron Letters, 37 (32), 5679.
103. Blagg, B.S.J. and Boger, D.L. (2002) Total synthesis of ({thorn})-camptothecin. Tetrahedron, 58, 6343-6349.
104. Bennasar, M.L., Zulaica, E., Juan, C., Alonso, Y., and Bosch, J. (2002) Addition of ester enolates to N-alkyl-2-fluoropyridinium salts: total synthesis of ({thorn}/-)-20-deoxycamptothecin and ({thorn})-camptothecin. The Journal of Organic Chemistry, 67 (21), 7465-7474.
105. Ciufolini, M.A. and Roschangar, F. (1996) Total synthesis of ({thorn})-camptothecin. Angewandte Chemie -International Edition in English, 35, 1692.
106. Ciufolini, M.A. and Roschangar, F. (1997) Practical total synthesis of ({thorn})-camptothecin: the full story. Tetrahedron, 53 (32), 11049-11060.
107. Ciufolini, M.A. and Roschangar, F. (2000) Practical synthesis of (20S)-({thorn}) camptothecin: the progenitor of a promising group of anticancer agents. Targets in Heterocyclic Systems, 4, 25.
108. Chavan, S.P. and Venkatraman, M.S. (1998) A practical and efficient synthesis of (±)-camptothecin. Tetrahedron Letters, 39 (37), 6745-6748.
109. Henegar, K.E., Ashford, S.W., Baughman, T. A., Sih, J.C.L., and Gu, R.L. (1997) Practical asymmetric synthesis of (S)-4-ethyl-7,8-dihydro-4-hydroxy-1H-pyrano[3,4-f] indolizine-3,6,10(4H)-trione, a key intermediate for the synthesis of irinotecan and other camptothecin analogs. The Journal of Organic Chemistry, 62 (19), 6588-6597.
110. Nguyen, T., Wicki, M.A., and Snieckus, V. (2004) Combined directed ortho metalation/cross-coupling strategies: synthesis of the tetracyclic A/B/C/D ring core of the antitumor agent camptothecin. The Journal of Organic Chemistry, 69 (23), 7816-7821.
111. Anderson, R.J., Raolji, G.B., Kanazawa, A., and Greene, A.E. (2005) A novel, expeditious synthesis of racemic camptothecin. Organic Letters, 7 (14), 2989-2991.
112. Tang, C.J., Babjak, M., Anderson, R.J., Greene, A.E., and Kanazawa, A. (2006) Novel, efficient total synthesis of natural 20 (S)-camptothecin. Organic & Biomolecular Chemistry, 4 (20), 3757-3759.
113. Murata, N., Sugihara, T., Kondo, Y., and Sakamoto, T. (1997) Synthesis of functionalized heteroaromatics: application to formal total synthesis of camptothecin. Synlett, 3, 298-300.
114. Chavan, S.P. and Sivappa, R. (2004) A synthesis of camptothecin. Tetrahedron Letters, 45 (15), 3113-3115.
115. Yu, S., Huang, Q.Q., Luo, Y., and Lu, W. (2012) Total synthesis of camptothecin and SN-38. The Journal of Organic Chemistry, 77, 713-717.
116. Curran, D.P., Ko, S.B., and Josien, H. (1996) Cascade radical reactions of isonitriles: a second-generation synthesis of (20S)-camptothecin, topotecan, irinotecan, and GI-147211C. Angewandte Chemie -International Edition in English, 34 (23-24), 2683-2684.
117. Kehrer, D.F., Soepenberg, O., Loos, W.J., Verweil, J., and Sparreboom, A. (2001) Modulation of camptothecin analogs in the treatment of cancer: a review. Anti-Cancer Drugs, 12, 89-105.
118. Dallavalle, S., Delsoldato, T., Ferrari, A., Merlini, L., Penco, S., Carenini, N., Perego, P., De Cesare, M., Pratesi, G., and Zunino, F. (2000) Novel 7-substituted camptothecins with potent antitumor activity. Journal of Medicinal Chemistry, 43 (21), 3963-3969.
119. Duan, J.X., Cai, X., Meng, F., Sun, J.D., Liu, Q., Jung, D., Jiao, H., Matteucci, J., Jung, B., Bhupathi, D., Ahluwalia, D., Huang, H., Hart, C.P., and Matteucci, M. (2011) 14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment. Journal of Medicinal Chemistry, 54, 1715-1723.
120. Lavergne, O., Lesueur-Ginot, L., Rodas, F.P., Kasprzyk, P.G., Pommier, J., Demarquay, D., Prevost, G., Ulibarri, G., Rolland, A., Schiano-Liberatore, A.M., Harnett, J., Pons, D., Camara, J., and Bigg, D.C. (1998) Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. Journal of Medicinal Chemistry, 41 (27), 5410-5419.
121. Sawada, S., Matsuoka, S., Nokata, K., Nagata, H., Furata, T., Yokokura, T., and Miyasaka, T. (1991) Synthesis and antitumor activity of 20(S)-camptothecin derivatives: A-ring modified and 7,10-disubstituted camptothecins. Chemical & Pharmaceutical Bulletin, 12, 3183-3188.
122. Cheng, K., Rahier, N.J., Eisenhauer, B.M., Gao, R., Thomas, S.J., and Hecht, S.M. (2005) 14-Azacamptothecin: A potent water-soluble topoisomerase I poison. Journal American Chemical Society, 127, 838-839.
123. Rahier, N.J., Cheng, Gao, K.R., Eisenhauer, B.M., and Hecht, S.M. (2005) Synthesis of 14-azacamptothecin, a water-soluble topoisomerase I poison. Organic Letters, 7 (5), 835-837.
124. Mi, Z. and Burke, T. (1994) Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry, 33, 10325-10336.
125. Mi, Z., Malak, H., and Burke, T.G. (1995) Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry, 34, 13722-13728.
126. Torchilin, V.P. and Schäfer-Korting, M. (2010) Handbook of Experimental Pharmacology, Springer, Berlin, p. 3.
127. Dal Pozzo, A., Ni, M.H., Esposito, E., Dallavalle, S., Musso, L., Bargiotti, A., Pisano, C., Vesci, L., Bucci, F., Castorina, M., Foderà, R., Giannini, G., Aulicino, C., and Penco, S. (2010) Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation. Bioorganic & Medicinal Chemistry, 18 (1), 64-72.
128. 3 integrin ligands: an approach to tumor-targeted therapy. Bioconjugate Chemistry, 21 (11), 1956-1967.
129. Huang, B., Desai, A., Tang, S., Thomas, T.P., and Baker, J.R. (2010) The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release. Organic Letters, 12, 1384-1387.
130. Alloatti, D., Giannini, G., Vesci, L., Castorina, M., Pisano, C., Badaloni, E., and Cabri, W. (2012) Camptothecins in tumor homing via an RGD sequence mimetic. Bioorganic & Medicinal Chemistry Letters, 22 (20), 6509-6512.
131. Lee, M.H., Kim, J.Y., Han, J.H., Bhuniya, S., Sessler, J.L., Kang, C., and Kim, J.S. (2012) Direct fluorescence monitoring of the delivery and cellular uptake of a cancer-targeted RGD peptide-appended naphthalimide theragnostic prodrug. Journal of the American Chemical Society, 134 (30), 12668-12674.
132. Cengelli, F., Grzyb, J.A., Montoro, A., Hofman, H., Hanessian, S., and Juillerat-Jeanneret, L. (2009) Surface-functionalized ultrasmall superparamagnetic nanoparticles as magnetic delivery vectors for camptothecin. ChemMedChem, 4 (6), 988-997.
133. Hanessian, S., Grzyb, J.A., Cengelli, F., and Juillerat-Jeanneret, L. (2008) Synthesis of chemically functionalized superparamagnetic nanoparticles as delivery vectors for chemotherapeutic drugs. Bioorganic & Medicinal Chemistry, 16 (6), 2921-2931.
134. Badaloni, E., Cabri, W., Ciogli, A., Deias, R., Gasparrini, F., Giorgi, F., Vigevani, A., and Villani, C. (2007) Combination of HPLC "inverted chirality columns approach" and MS/MS detection for extreme enantiomeric excess determination even in absence of reference samples: application to camptothecin derivatives. Analytical Chemistry, 79 (15), 6013-6019.
135. Gasparrini, F., Ciogli, A., D'Acquarica, I., Misiti, D., Badaloni, E., Giorgi, F., and Vigevani, A. (2007) Synthesis and characterization of novel internal surface reversed-phase silica supports for high-performance liquid chromatography. Journal of Chromatography, 1176, 79-88.
136. Taki, H., Kanazawa, T., Akiyama, F., Takashima, Y., and Okada, H. (2012) Intranasal delivery of camptothecin-loaded Tat-modified nanomicells for treatment of intracranial brain tumors. Pharmaceuticals, 5, 1092-1102.